Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 101 clinical trials
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

-small cell lung cancer who have progressed after 1 or 2 lines of therapies. The primary objectives of the study are to evaluate the overall response rate of subjects treated with CC-90011 in

platinum-based chemotherapy
nivolumab
primary cancer
gilbert's syndrome
lung cancer
  • 0 views
  • 08 May, 2021
  • 41 locations
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are three parts to this study. In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). In …

solid tumour
bevacizumab
tyrosine
cancer
kinase inhibitor
  • 226 views
  • 08 May, 2021
  • 48 locations
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

BRAF
platinum-based chemotherapy
cancer
extensive disease
human epidermal growth factor
  • 12 views
  • 07 May, 2021
  • 56 locations
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth …

cancer
pemetrexed
stage iv non-small cell lung cancer
systemic chemotherapy
lung cancer
  • 238 views
  • 07 Mar, 2021
  • 189 locations
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (SQ-NSCLC). Subjects may participate in the pre-screening phase at initial diagnosis or following prior lines of therapy

lung carcinoma
HRAS
kidney function test
secondary malignant neoplasm of liver
platelet count
  • 14 views
  • 23 Jan, 2021
  • 35 locations
Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line ALTER-L020

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase. In the phase III study, Patients who failed at least two kinds of systemic chemotherapy (third line or …

  • 0 views
  • 24 Jan, 2021
  • 1 location
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From Non-squamous NSCLC

non-squamous non-small cell lung cancer by assessing the treatment response, perilesional edema, neurological symptoms and quality of life.

contrast-enhanced mri
tyrosine
bevacizumab
fractionated stereotactic radiotherapy
lung cancer
  • 1 views
  • 24 Jan, 2021
  • 1 location
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

This study is a single-arm, prospective, multi-center clinical trial. designed to evaluate patients with stage IV inability to receive or refuse chemotherapy.Efficacy and safety of first-line treatment with Camrelizumab and Endo in advanced lung squamous cell carcinoma

lung carcinoma
adjuvant chemotherapy
cancer chemotherapy
squamous cell carcinoma
chemoradiotherapy
  • 0 views
  • 23 Jan, 2021
  • 1 location
  • 3 views
  • 24 Jan, 2021
  • 2 locations
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small

  • 0 views
  • 07 May, 2021
  • 1 location